CD1A and prostate cancer: Heterogeneity in hypomethylation at CD1A-IFI16 is evident within single prostate cancer cells at early stage GS6 tumors, progressively increasing in both fraction of tumor cells and degree of hypomethylation within individual tumor cells as they evolve to GS8 and ultimately to metastatic CTCs (Figures 4C and S5A).